CureDuchenne is very proud that Dr. Kevin Flanigan, at Nationwide Children’s Hospital, has treated two patients with gene therapy that carry the Duplication 2 mutation. CureDuchenne funded Dr. Flanigan’s very […]
Take this Survey by July 19! CureDuchenne is supporting the EveryLife Foundation for Rare Diseases in their effort to conduct a survey of families living with rare diseases. This survey […]
Friday, May 15, 2020 – 8:00amEDT Pfizer Inc. (NYSE: PFE) today announced updated Phase 1b clinical data on PF-06939926, an investigational gene therapy being developed to treat Duchenne muscular dystrophy […]
CureDuchenne Ventures is happy to announce its latest investment in Myosana Therapeutics, a new biotech company based in Seattle, WA. Myosana is aiming to develop next-generation gene therapy for Duchenne muscular dystrophy and other neuromuscular […]
Dear Duchenne Community, I’m truly thrilled about our investment in a new biotech company called Myosana Therapeutics. Myosana aims to develop next-generation gene therapy for Duchenne muscular dystrophy and neuromuscular diseases. Because of this investment, the team is now positioned to conduct […]
Dear Duchenne Community, We are proud that, through these difficult times, CureDuchenne is continuing to invest in research, to expand our programs and offer services to the Duchenne Community. All of us are feeling the personal, emotional and financial toll […]
Author: Erin Frey, Senior Director of Advocacy, CureDuchenne Watching the news over the last few weeks has ranged from confusing to disheartening, overwhelming and sometimes, let’s admit it, a little […]
Today, we are extremely excited to announce a new partnership with Dyne Therapeutics, an innovative organization whose FORCE™ Platform is working to bring transformational therapies for serious muscle diseases, including […]
